News - Valeant Pharmaceuticals, North America


Popular Filters

Valeant agrees $142.5 million settlement with Anacor


Anacor Pharmaceuticals says it has entered into a $142,5 million settlement agreement with Canada-based…

Anacor PharmaceuticalsFinancialLegalNorth AmericaPharmaceuticalValeant Pharmaceuticals

Anacor Pharma awarded $100 million damages


Anacor Pharmaceuticals says that the arbitrator appointed to resolve its dispute with Canada-based Valeant…

Anacor PharmaceuticalsLegalNorth AmericaPharmaceuticalValeant Pharmaceuticals

FDA grants "Breakthrough Therapy" status for Alexion's asfotase in HPP; issues CRL for Valeant's efinaconazole


US drugmaker Alexion Pharmaceuticals (Nasdaq: ALXN) says that the Food and Drug Administration has granted…

Alexion PharmaceuticalsAntibiotics and Infectious diseasesasfotase alfaefinaconazoleNorth AmericaPharmaceuticalRare diseasesRegulationValeant Pharmaceuticals

ISTA Pharma pleads guilty to federal felony charges in $33.5 million settlement; parent Bausch & Lomb a Valeant takeover target?


US drugmaker ISTA Pharmaceuticals has pleaded guilty to conspiracy to introduce a misbranded drug into…

Bausch & LombISTA PharmaceuticalLegalMarkets & MarketingMergers & AcquisitionsNorth AmericaPharmaceuticalValeant PharmaceuticalsXibrom

Actavis in OxyContin patent settlement; Valeant takeover bid "on hold"?


US generic major Actavis (NYSE: ACT) has entered into an agreement with privately-held Purdue Pharma…

ActavisGenericsMergers & AcquisitionsNeurologicalNorth AmericaOxyContinPatentsPurdue PharmaValeant Pharmaceuticals

Actavis settles with Valeant to launch generic Ziana and Zyclara in USA


US generics drug major Actavis (NYSE: ACT) has reached settlement agreements with Medicis Pharmaceutical,…

ActavisGenericsMarkets & MarketingNorth AmericaPatentsValeant PharmaceuticalsZiana GelZyclara

Actavis and Valeant to co-promote Zovirax and Cordran Tape


Valeant Pharmaceuticals International (TSX: VRX) entered into an agreement, effective immediately, for…

ActavisAnti-viralsCordran TapeGenericsLicensingMarkets & MarketingMylan LaboratoriesNorth AmericaValeant PharmaceuticalsZovirax Ointment

Valeant Pharma buys US rights to Eisai's Targretin for $65 million upfront


Canada's Valeant Pharmaceuticals International (TSX: VRX) says that it has acquired US rights for Targretin…

EisaiLicensingNorth AmericaOncologyPharmaceuticalTargretinValeant Pharmaceuticals

News briefs from Bayer, AstraZeneca and Valeant/Galderma


German drug major Bayer (BAYN: DE) and partner Regeneron (Nasdaq: REGN) submitted a marketing application…

AstraZenecaBayerEuropeEyleaFaslodexGaldermaLicensingNorth AmericaOncologyOphthalmicsPerlanePharmaceuticalRegulationRestylaneValeant Pharmaceuticals

Depomed to file NDA for Serada; with Valeant sues Watson over Glumetza


US drugmaker Depomed (Nasdaq: DEPO) says that it has completed a Type B pre-New Drug Application meeting…

DepomedDiabetesGenericsGlumetzaNorth AmericaPatentsPharmaceuticalRegulationResearchSeradaValeant PharmaceuticalsWatson PharmaceuticalsWomen's Health

FTC stipulates divestments for Valeant acquisitions


Canada’s Valeant Pharmaceuticals International (TSX: VRX) has been ordered by the USA’s Federal…

DermatologicalsDermikMergers & AcquisitionsNorth AmericaPharmaceuticalValeant Pharmaceuticals

BioDelivery pain drug Onsolis to launch in Canada via Meda Valeant


US specialty drug firm BioDelivery Sciences International (Nasdaq: BDSI) says that its pain drug Onsolis…

BioDelivery SciencesMarkets & MarketingMedaMeda ValeantNeurologicalNorth AmericaOnsolisPharmaceuticalValeant Pharmaceuticals

Valeant back on takeover path, now eyeing Sweden’s Meda: Canada OKs Sublinox


Unconfirmed press reports indicate that Canada’s Valeant Pharmaceutical International (NYSE: VRX)…

Markets & MarketingMedaNeurologicalNorth AmericaPharmaceuticalRegulationSublinoxValeant Pharmaceuticals

Back to top